Formerly dba West Coast Biologicals Inc, Vaxart, Inc.,(NASDAQ:VXRT) a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. Vaxart is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Publicly traded since April 2016, the firm achieved that status through use of the vehicle of reverse merger with antivirals developer Aviragen Therapeutics Inc. Vaxart is organized around developing oral recombinant protein vaccines administered using a convenient room temperature-stable tablet, rather than by injection. Vaxartâs oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. The Company is developing prophylactic vaccine candidates that target a range of infectious diseases, including norovirus, a widespread cause of acute gastrointestinal distress for which two Phase 1 human studies have been completed; seasonal influenza, for which a Phase 2 challenge study was recently completed; and respiratory syncytial virus, or RSV, a common cause of respiratory tract infections. In addition, Vaxart is also developing its first therapeutic vaccine targeting cervical cancer and dysplasia caused by HPV types 16 and 18
